Senator Grassley seeks info on Novartis’s Zolgensma data issues

U.S. Senate Finance Committee Chairman Chuck Grassley has asked Swiss drugmaker Novartis AG to provide details on data manipulation related to its $2 million gene therapy, Zolgensma, by Aug. 23.


Read More

Sharing is caring!